MarieBleuenn Terrier - Cellectis General Counsel, Member of the Executive Committee
CMVLF Stock | USD 1.25 0.00 0.00% |
Executive
Ms. MarieBleuenn Terrier was General Counsel and Member of the Executive Committee of Cellectis since 2013. Prior to joining Cellectis, she worked as Legal Counsel for Pfizer from 2004 to 2006, and for Boehringer Ingelheim from 2006 to 2008. She holds a Masters degree in Law from Universite Paris 1 PantheonSorbonne. since 2013.
Age | 41 |
Tenure | 12 years |
Phone | 33 1 81 69 16 00 |
Web | https://www.cellectis.com |
Cellectis Management Efficiency
The company has return on total asset (ROA) of (0.2408) % which means that it has lost $0.2408 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.557) %, meaning that it generated substantial loss on money invested by shareholders. Cellectis' management efficiency ratios could be used to measure how well Cellectis manages its routine affairs as well as how well it operates its assets and liabilities.Cellectis SA has accumulated 18.77 M in total debt with debt to equity ratio (D/E) of 0.52, which is about average as compared to similar companies. Cellectis SA has a current ratio of 3.11, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Cellectis until it has trouble settling it off, either with new capital or with free cash flow. So, Cellectis' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cellectis SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cellectis to invest in growth at high rates of return. When we think about Cellectis' use of debt, we should always consider it together with cash and equity.
Management Performance
Return On Equity | -0.56 | |||
Return On Asset | -0.24 |
Cellectis SA Leadership Team
Elected by the shareholders, the Cellectis' board of directors comprises two types of representatives: Cellectis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cellectis. The board's role is to monitor Cellectis' management team and ensure that shareholders' interests are well served. Cellectis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cellectis' outside directors are responsible for providing unbiased perspectives on the board's policies.
Andre Choulika, Chairman of the Board and CEO, Member of the Executive Committee | ||
MarieBleuenn Terrier, General Counsel, Member of the Executive Committee | ||
Dr MBA, Chief Officer | ||
David Sourdive, Co-Founder, Executive VP of Corporate Devel. and Director | ||
Valerie Cros, Principal Officer | ||
Kyung NamWortman, Ex Officer | ||
Philippe Duchateau, Chief Scientific Officer | ||
Pascalyne Wilson, Director Communications | ||
Jean Epinat, Chief Officer | ||
MSc MSc, Chief Officer |
Cellectis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Cellectis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.56 | |||
Return On Asset | -0.24 | |||
Operating Margin | (6.01) % | |||
Current Valuation | 82.79 M | |||
Shares Outstanding | 55.59 M | |||
Shares Owned By Institutions | 9.80 % | |||
Price To Earning | (13.64) X | |||
Price To Book | 0.79 X | |||
Price To Sales | 4.79 X | |||
Revenue | 57.29 M |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Cellectis Pink Sheet
When determining whether Cellectis SA is a strong investment it is important to analyze Cellectis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cellectis' future performance. For an informed investment choice regarding Cellectis Pink Sheet, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectis SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.